The growth in the historic period can be attributed to increasing incidence of diffuse large b-cell lymphoma, rising adoption of biologic cancer therapies, expansion of oncology treatment infrastructure, growing clinician familiarity with monoclonal antibodies, availability of advanced infusion facilities.
The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investments in oncology biologics research, expansion of combination therapy approvals, growing focus on outpatient oncology care, increasing adoption of targeted immunotherapies. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising use of combination regimens in lymphoma treatment, growing focus on precision oncology approaches, expansion of cd19-directed therapeutic applications, enhanced emphasis on improved patient outcomes.
The rising prevalence of cancer is expected to drive the growth of the Minjuvi (Monjuvi) market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer can be attributed to factors such as aging, lifestyle choices like smoking and poor diet, environmental exposures, genetic predispositions, and improved detection methods. Minjuvi (Monjuvi), in combination with lenalidomide, is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), offering enhanced treatment options by effectively targeting cancer cells. For example, in August 2024, the Australian Institute of Health and Welfare, a national agency for information and statistics on Australia's health, projected that by 2034, approximately 209,000 new cancer diagnoses will occur in Australia, up from the estimated 169,000 cases in 2024. Additionally, cancer is expected to account for about 3 out of every 10 deaths in the country in 2024. Therefore, the increasing prevalence of cancer is fueling the growth of the Minjuvi (Monjuvi) market.
A key trend in the Minjuvi (Monjuvi) market is the development of innovative therapies, such as combination therapies, to improve treatment efficacy and outcomes for patients with B-cell malignancies, especially those with relapsed or refractory DLBCL. Combination therapy involves using two or more treatments together to target different pathways or mechanisms involved in the disease, thereby enhancing overall treatment effectiveness. For instance, in February 2024, Knight Therapeutics Inc., a Canada-based pharmaceutical company, launched Minjuvi (tafasitamab) through its Brazilian affiliate, United Medical Ltda. In combination with lenalidomide, Minjuvi is used to treat relapsed or refractory DLBCL patients who are ineligible for autologous stem cell transplantation. The combination has demonstrated a significant objective response rate and is considered a preferred second-line treatment according to NCCN guidelines.
In February 2024, Incyte Corporation, a US-based pharmaceutical company, acquired full rights to Monjuvi from MorphoSys AG for $25 million. This acquisition allows Incyte to have complete control over Monjuvi's global commercialization and clinical development, enhancing operational efficiencies and driving cost synergies. It also positions Incyte to capitalize on the drug's potential to expand its indications for lymphoma treatment. MorphoSys AG, a Germany-based biotech company, specializes in developing Monjuvi.
Major companies operating in the minjuvi or monjuvi market are Incyte Corporation.
North America was the largest region in the minjuvi or monjuvi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minjuvi or monjuvi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minjuvi or monjuvi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the minjuvi or monjuvi market by increasing costs associated with imported biologic manufacturing inputs, specialized cell culture media, single-use bioprocessing equipment, and cold-chain logistics components. Oncology drug supply chains in North America and Europe are most affected due to reliance on globally sourced biologic raw materials and manufacturing technologies, while Asia-Pacific faces higher costs in active pharmaceutical ingredient processing. These tariffs are contributing to higher production and distribution expenses, potentially influencing pricing strategies. However, they are also encouraging localized biologics manufacturing, regional contract manufacturing partnerships, and long-term investments in domestic biopharmaceutical production capacity.
The minjuvi or monjuvi market research report is one of a series of new reports that provides minjuvi or monjuvi market statistics, including minjuvi or monjuvi industry global market size, regional shares, competitors with a minjuvi or monjuvi market share, detailed minjuvi or monjuvi market segments, market trends and opportunities, and any further data you may need to thrive in the minjuvi or monjuvi industry. This minjuvi or monjuvi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Minjuvi (tafasitamab) is a monoclonal antibody used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) by targeting and binding to CD19 on malignant B cells. This triggers immune system-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC) and apoptosis, helping to reduce tumor burden by eliminating cancerous B cells while sparing normal ones.
The main indications for Minjuvi, also known as Monjuvi, include relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other related conditions. Relapsed or refractory DLBCL refers to cases where the lymphoma returns after treatment or does not respond to initial therapy. Minjuvi is administered via intravenous infusion or pre-filled syringes. Its distribution channels include hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various patient demographics, including adult and geriatric patients.
The minjuvi or monjuvi market consists of sales of monoclonal antibody therapies, combination therapies, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investments in oncology biologics research, expansion of combination therapy approvals, growing focus on outpatient oncology care, increasing adoption of targeted immunotherapies. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising use of combination regimens in lymphoma treatment, growing focus on precision oncology approaches, expansion of cd19-directed therapeutic applications, enhanced emphasis on improved patient outcomes.
The rising prevalence of cancer is expected to drive the growth of the Minjuvi (Monjuvi) market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer can be attributed to factors such as aging, lifestyle choices like smoking and poor diet, environmental exposures, genetic predispositions, and improved detection methods. Minjuvi (Monjuvi), in combination with lenalidomide, is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), offering enhanced treatment options by effectively targeting cancer cells. For example, in August 2024, the Australian Institute of Health and Welfare, a national agency for information and statistics on Australia's health, projected that by 2034, approximately 209,000 new cancer diagnoses will occur in Australia, up from the estimated 169,000 cases in 2024. Additionally, cancer is expected to account for about 3 out of every 10 deaths in the country in 2024. Therefore, the increasing prevalence of cancer is fueling the growth of the Minjuvi (Monjuvi) market.
A key trend in the Minjuvi (Monjuvi) market is the development of innovative therapies, such as combination therapies, to improve treatment efficacy and outcomes for patients with B-cell malignancies, especially those with relapsed or refractory DLBCL. Combination therapy involves using two or more treatments together to target different pathways or mechanisms involved in the disease, thereby enhancing overall treatment effectiveness. For instance, in February 2024, Knight Therapeutics Inc., a Canada-based pharmaceutical company, launched Minjuvi (tafasitamab) through its Brazilian affiliate, United Medical Ltda. In combination with lenalidomide, Minjuvi is used to treat relapsed or refractory DLBCL patients who are ineligible for autologous stem cell transplantation. The combination has demonstrated a significant objective response rate and is considered a preferred second-line treatment according to NCCN guidelines.
In February 2024, Incyte Corporation, a US-based pharmaceutical company, acquired full rights to Monjuvi from MorphoSys AG for $25 million. This acquisition allows Incyte to have complete control over Monjuvi's global commercialization and clinical development, enhancing operational efficiencies and driving cost synergies. It also positions Incyte to capitalize on the drug's potential to expand its indications for lymphoma treatment. MorphoSys AG, a Germany-based biotech company, specializes in developing Monjuvi.
Major companies operating in the minjuvi or monjuvi market are Incyte Corporation.
North America was the largest region in the minjuvi or monjuvi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minjuvi or monjuvi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minjuvi or monjuvi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the minjuvi or monjuvi market by increasing costs associated with imported biologic manufacturing inputs, specialized cell culture media, single-use bioprocessing equipment, and cold-chain logistics components. Oncology drug supply chains in North America and Europe are most affected due to reliance on globally sourced biologic raw materials and manufacturing technologies, while Asia-Pacific faces higher costs in active pharmaceutical ingredient processing. These tariffs are contributing to higher production and distribution expenses, potentially influencing pricing strategies. However, they are also encouraging localized biologics manufacturing, regional contract manufacturing partnerships, and long-term investments in domestic biopharmaceutical production capacity.
The minjuvi or monjuvi market research report is one of a series of new reports that provides minjuvi or monjuvi market statistics, including minjuvi or monjuvi industry global market size, regional shares, competitors with a minjuvi or monjuvi market share, detailed minjuvi or monjuvi market segments, market trends and opportunities, and any further data you may need to thrive in the minjuvi or monjuvi industry. This minjuvi or monjuvi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Minjuvi (tafasitamab) is a monoclonal antibody used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) by targeting and binding to CD19 on malignant B cells. This triggers immune system-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC) and apoptosis, helping to reduce tumor burden by eliminating cancerous B cells while sparing normal ones.
The main indications for Minjuvi, also known as Monjuvi, include relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other related conditions. Relapsed or refractory DLBCL refers to cases where the lymphoma returns after treatment or does not respond to initial therapy. Minjuvi is administered via intravenous infusion or pre-filled syringes. Its distribution channels include hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various patient demographics, including adult and geriatric patients.
The minjuvi or monjuvi market consists of sales of monoclonal antibody therapies, combination therapies, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Minjuvi or Monjuvi Market Characteristics
3. Minjuvi or Monjuvi Market Supply Chain Analysis
4. Global Minjuvi or Monjuvi Market Trends and Strategies
5. Minjuvi or Monjuvi Market Analysis of End Use Industries
7. Global Minjuvi or Monjuvi Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Minjuvi or Monjuvi Total Addressable Market (TAM) Analysis for the Market
9. Minjuvi or Monjuvi Market Segmentation
10. Minjuvi or Monjuvi Market Regional and Country Analysis
11. Asia-Pacific Minjuvi or Monjuvi Market
12. China Minjuvi or Monjuvi Market
13. India Minjuvi or Monjuvi Market
14. Japan Minjuvi or Monjuvi Market
15. Australia Minjuvi or Monjuvi Market
16. South Korea Minjuvi or Monjuvi Market
17. Western Europe Minjuvi or Monjuvi Market
18. UK Minjuvi or Monjuvi Market
19. Germany Minjuvi or Monjuvi Market
20. France Minjuvi or Monjuvi Market
21. Eastern Europe Minjuvi or Monjuvi Market
22. North America Minjuvi or Monjuvi Market
23. USA Minjuvi or Monjuvi Market
24. Canada Minjuvi or Monjuvi Market
25. South America Minjuvi or Monjuvi Market
26. Middle East Minjuvi or Monjuvi Market
27. Africa Minjuvi or Monjuvi Market
29. Minjuvi or Monjuvi Market Competitive Landscape and Company Profiles
32. Minjuvi or Monjuvi Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Minjuvi Or Monjuvi Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses minjuvi or monjuvi market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for minjuvi or monjuvi? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The minjuvi or monjuvi market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Relapsed Or Refractory Diffuse Large B-cell Lymphoma (DLBCL); Other B-Cell Malignancies2) By Formulation: Intravenous Infusion; Pre-Filled Syringes
3) By Distribution Channel: Hospitals; Oncology Clinics; Specialty Pharmacies; Home Healthcare Services
4) By End User Patients: Adult Patients; Geriatric Patients
Companies Mentioned: Incyte Corporation
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Minjuvi or Monjuvi market report include:- Incyte Corporation
